PRIME POLICY GROUP

Lobbying for KEDRION BIOPHARMA · Production of Plasma-Derived Therapies

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · New Jersey · $170,000.00 income · posted Oct 20, 2025

Lobbying activity 1

Trade (domestic/foreign)

Pharmaceutical tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem